Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

sponse and side effects such as heightened blood pressure.

Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients often report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

LEVADEX and TEMPO are trademarks of MAP Pharmaceuticals, Inc.

Forward-Looking Statements


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "MEMS Gyroscopes ... Costing Analysis" report to their offering. ... MEMS gyroscopes for tactical grade applications made a ... in term of reliability. They are now accepted ...
(Date:12/15/2014)... , December 15, 2014 ... drugs for aggressive drug resistant cancers, today announces that ... a private placing from new and existing investors. ... to support the development of its pipeline of innovative ... for its lead drug candidate, BGB324, a first-in-class selective ...
(Date:12/15/2014)... Washington State are not the only ... Oregon , Alaska , and ... 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are the ... revenue for state and local governments, in addition to reduced ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... Ill., April 1, 2011 Hospira ... of clinical information and medication delivery technologies, today announced ... system , used by hospitals to help improve patient ... (HAIs). The enhanced TheraDoc system includes new features and ...
... & Dempsey is launching Accountable Care Forum - ... analysis of the emerging accountable care organization (ACO) landscape. ... Centers for Medicare & Medicaid Services (CMS). ... reform legislation affecting physicians and hospitals across the United ...
Cached Medicine Technology:Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care 2Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care 3Online Forum for Accountable Care Organization Developments Launches Today; Squire Sanders Sponsorship Reflects Commitment to Leadership in Emerging Health Policy Debate 2
(Date:12/17/2014)... No matter how far modern medicine advances, it ... louse parasite—a common childhood malady and a source of ... and twelve million individuals will suffer an infestation. ... comes to the rescue, providing an all-natural treatment that ... record of customer service, and effectiveness in getting rid ...
(Date:12/17/2014)... 15, 2014 (HealthDay News) -- As gas prices rose ... a new study suggests. In times of gas ... those riders are inexperienced, the researchers explained. They ... which has the highest number of motorcycle registrations in ... motorcyclist deaths. The analysis revealed a strong association ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Poor students get more ... a new study finds. But, the opposite is true ... having fruits and vegetables at school may give a healthy ... But, no matter what the family income level, students all ... the study found. The study was published recently in ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... researchers have just published an important new report on ... mesothelioma. Surviving Mesothelioma has just posted an article on ... read it now. , Doctors at Harvard, MIT, ... Langone Medical Center performed complete genetic analyses on 22 ... to pinpoint the genes that are most likely to ...
Breaking Medicine News(10 mins):Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2
... Food Safety in Sunshine State by Using ... Food-Borne Illness, LANSING, Ill., Feb. 7 National ... Egg restaurants in,Lakewood Ranch and Sarasota, Fla., will now ... for all dishes requiring eggs., By using Davidson,s ...
... Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... People,s Republic of China ("PRC"), today,announced that ... owned,subsidiary of Lotus, has implemented cost saving ... costs by approximately 50%., The environmentally-friendly ...
... hours and more than 300 people in the UK die ... with permanent disabilities. Now researchers will work on a potential ... the medical charity Meningitis UK. , Although vaccines exist to ... vaccine to protect against all strains, including the most common ...
... E. Borlaug Hall of Laureates, DES MOINES, Iowa, ... a $1 million contingent donation to fund the establishment,of ... Des Moines. The donation,will support the transformation of the ... Hall of Laureates and will be administered,through DuPont business ...
... New Fresh Plum Juice Boasts Digestive Health Benefits with 60 Percent Less ... ... Due to the overwhelming,success of PlumSmart plum juice, Sunsweet Growers Inc. has ... three grams of fiber in each glass and only 11 grams of,sugar, ...
... All Existing Markets -, LONG BEACH, N.Y., Feb. ... PMQCW), the third largest long-term care,pharmacy, today announced that ... across all four of its institutional pharmacies,which serve a ... City,metropolitan area, as well as parts of New Jersey, ...
Cached Medicine News:Health News:Popular Florida Restaurant Leads Hospitality Industry by Converting to Pasteurized Shell Eggs Usage 2Health News:Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies 2Health News:Meningitis vaccine study gets £200,000 boost 2Health News:DuPont Pledges $1 Million to World Food Prize 2Health News:DuPont Pledges $1 Million to World Food Prize 3Health News:Sunsweet Introduces PlumSmart Light(R) 2Health News:Chem Rx Surpasses 65,000 Residents Served 2
... The Cholestech LDX System, using patented, innovative ... glucose and ALT in only 5 minutes ... ALT test, you can get immediate liver ... capabilities is not the only advantage to ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: